All In Biotech

Drug Trial Radar · NCT02213289

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Apr 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Jan 20, 2015

Primary completion

Feb 1, 2020

Study completion Aug 20, 2020

Sponsor

Lead sponsor
University of ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
AbbVie
First posted
Aug 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.

Conditions

  • Adenocarcinoma

Interventions

  • TrastuzumabDrug

    Trastuzumab

  • ABT-806Drug

    ABT-806

  • BemarituzumabDrug

    Bemarituzumab

  • RamucirumabDrug

    Ramucirumab

  • NivolumabDrug

    Nivolumab

  • Standard cytotherapyDrug

    FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Up to 60 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.